Reference

Febuxostat: a novel, non-purine xanthine oxidase inhibitor

All Rights Reserved. Febuxostat: a novel, non-purine xanthine oxidase inhibitor. Kim, Karissa Y.; Wigle, Patricia R. (College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA). Journal of Pharmacy Technology, 22(6), 342-348 (English) 2006 Harvey Whitney Books Co. CODEN: JPTEEB. ISSN: 8755-1225. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Objective: To review the pharmacol. and clin. data for febuxostat in the treatment of gout and hyperuricemia. Data Sources: Articles on febuxostat published in English between 1966 and Nov. 2006 were identified through a MEDLINE search using the key words febuxostat, TEI-6720, TMX-67, gout, and hyperuricemia. Addnl. articles were identified through search of the publications' ref. lists. Abstrs. from the 2005 proceedings of the American College of Rheumatol., American College of Clin. 144060-53-7 and 69-93-2 which are cas registry numbers are also used here. Pharmacol., and American Society for Clin. Pharmacol. and Therapeutics were also searched for febuxostat studies. Study Selection and Data Extn.: All published febuxostat trials in humans were selected for this review. Clin., pharmacokinetic, and pharmacodynamic data were evaluated. Data Synthesis: Febuxostat is a non-purine, selective inhibitor of xanthine oxidase that has demonstrated efficacy in lowering serum uric acid levels in patients with hyperuricemia assocd. with gout. Compared with allopurinol 300 mg/day, febuxostat 80 or 120 mg/day was more effective in lowering serum uric acid levels to less than 6 mg/dL. Febuxostat appears to be safe, with the majority of treatment-related adverse events reported being transient and mild-to-moderate in severity. However, abnormal elevation of liver enzyme levels has been reported with its use. There have been no documented major drug interactions with febuxostat. Conclusions: Febuxostat is a novel, non-purine xanthine oxidase inhibitor undergoing review by the FDA. It represents a potential advancement in the treatment of hyperuricemia assocd. with gout. .

Protective agents for organs and tissues

Protective agents for organs and tissues.Several substances are used for example 144060-53-7 which is its cas registry number. Ota, Mikio; Horiuchi, Hideki; Kitahara, Shigehisa; Kondo, Shiro; Takano, Yasuhiro (Teijin Ltd., Japan). PCT Int. Appl. WO 9631211 A1 10 Oct 1996, 19 pp. DESIGNATED STATES: W: AU, CA, JP, KR, US; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-425. ICS: C07D277-56. APPLICATION: WO 1996-JP924 4 Apr 1996. PRIORITY: JP 1995-82576 7 Apr 1995. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) 2-Phenylthiazole derivs. and their salts are effective for the treatment of reactive oxygen-induced ischemia-reperfusion injuries in organs. A tablet contg. 50 mg 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiozolecarboxylic acid (I) was formulated. Administration of I to rats prior to induction of surgical ischemia prevented the increase in serum level of creatinine. .